Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13686450 | 0.81 | SLC6A4 (0.38) | GSK3BADORA3ADORA2AADORA1 | |
| SCHEMBL13686483 | 0.79 | IDO1 (0.32) | GSK3B | |
| SCHEMBL18237944 | 0.77 | CDC7 (0.47) | GSK3BCDC7CDK9 | |
| SCHEMBL10072303 | 0.76 | GSK3B (0.42) | GSK3BADORA3ADORA2AADORA1HTR2B | |
| SCHEMBL18237551 | 0.75 | HTR2A (0.33) | HTR2B | |
| SCHEMBL1118519 | 0.72 | CCKBR (0.42) | HTR2BCYP11B1CYP11B2 | |
| SCHEMBL12141050 | 0.72 | CCKBR (0.42) | HTR2BCYP11B1CYP11B2 | |
| SCHEMBL12013752 | 0.72 | CCKBR (0.42) | HTR2BCYP11B1CYP11B2 | |
| SCHEMBL24898422 | 0.72 | GSK3B (0.35) | GSK3BADORA3ADORA2AADORA1 | |
| SCHEMBL13913017 | 0.72 | GSK3B (0.35) | GSK3BADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | GSK3B 3558/4885ADORA3 130/4885ADORA2A 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.